Determination of teicoplanin trough concentration target and appropriate total dose during the first 3 days: a retrospective study in patients with MRSA infections

Wilson, 1994, A critical review of the dosage of teicoplanin in Europe and the USA, Int J Antimicrob Agents, 4, 1, 10.1016/0924-8579(94)90049-3 Harding, 2000, Comparative pharmacokinetics of teicoplanin and vancomycin, J Chemother, 12, 15, 10.1080/1120009X.2000.11782313 Rowland, 1990, Clinical pharmacokinetics of teicoplanin, Clin Pharmacokinet, 18, 184, 10.2165/00003088-199018030-00002 Kollef, 2001, Optimizing antibiotic therapy in the intensive care unit setting, Crit Care, 5, 189, 10.1186/cc1022 Niederman, 2003, Appropriate use of antimicrobial agents: challenges and strategies for improvement, Crit Care Med, 31, 608, 10.1097/01.CCM.0000050464.70382.D6 MacGowan, 1996, Retrospective review of serum teicoplanin concentrations in clinical trials and their relationship to clinical outcome, J Infect Chemother, 2, 197, 10.1007/BF02355116 MacGowan, 1998, Pharmacodynamics, pharmacokinetics, and therapeutic drug monitoring of glycopeptides, Ther Drug Monit, 20, 473, 10.1097/00007691-199810000-00005 Pea, 2006, The effect of multifactorial, multidisciplinary educational interventions on appropriate use of teicoplanin, Int J Antimicrob Agents, 27, 344, 10.1016/j.ijantimicag.2005.11.012 Pea, 2003, Teicoplanin therapeutic drug monitoring in critically ill patients: a retrospective study emphasizing the importance of a loading dose, J Antimicrob Chemother, 51, 971, 10.1093/jac/dkg147 Ito, 1993, Dose-finding study of teicoplanin in respiratory infections caused by Staphylococcus aureus, Jpn J Chemother, 41, 126 Yura, 1993, Clinical evaluation of teicoplanin in the treatment of skin and soft tissue infection, Jpn J Chemother, 41, 134 Nakamura, 2008, Appropriate use of the anti-methicillin-resistant Staphylococcus aureus agents in retrospective study, Yakugaku Zasshi, 128, 1073, 10.1248/yakushi.128.1073 2000 2000 Cockcroft, 1976, Prediction of creatinine clearance from serum creatinine, Nephron, 16, 31, 10.1159/000180580 Wood, 2000, Comparative safety of teicoplanin and vancomycin, J Chemother, 12, 21, 10.1080/1120009X.2000.11782314 Wilson, 2000, Clinical pharmacokinetics of teicoplanin, Clin Pharmacokinet, 39, 167, 10.2165/00003088-200039030-00001 MacGowan, 1992, Serum monitoring of teicoplanin, J Antimicrob Chemother, 30, 399, 10.1093/jac/30.3.399-a Begg, 2001, The therapeutic monitoring of antimicrobial agents, Br J Clin Pharmacol, 52, 35S, 10.1046/j.1365-2125.2001.00377.x Harding, 2000, Teicoplanin therapy for Staphylococcus aureus septicaemia: relationship between pre-dose serum concentrations and outcome, J Antimicrob Chemother, 45, 835, 10.1093/jac/45.6.835 Sato, 2006, Recommended initial loading dose of teicoplanin, established by therapeutic drug monitoring, and outcome in terms of optimal trough level, J Infect Chemother, 12, 185, 10.1007/s10156-006-0446-Y Lortholary, 1996, Population pharmacokinetic study of teicoplanin in severely neutropenic patients, Antimicrob Agents Chemother, 40, 1242, 10.1128/AAC.40.5.1242 Soy, 2006, Teicoplanin population pharmacokinetic analysis in hospitalized patients, Ther Drug Monit, 28, 737, 10.1097/01.ftd.0000249942.14145.ff Yano, 2007, Variability in teicoplanin protein binding and its prediction using serum albumin concentrations, Ther Drug Monit, 29, 399, 10.1097/FTD.0b013e3180690755 Pea, 2004, Teicoplanin in patients with acute leukaemia and febrile neutropenia: a special population benefiting from higher dosages, Clin Pharmacokinet, 43, 405, 10.2165/00003088-200443060-00004 Schaison, 2000, Teicoplanin in the treatment of serious infection, J Chemother, 12, 26, 10.1080/1120009X.2000.11782315 Wilson, 1993, Dosage recommendations for teicoplanin, J Antimicrob Chemother, 32, 792, 10.1093/jac/32.6.792 MacGowan, 1997, Pharmacodynamics of antimicrobial agents and rationale for their dosing, J Chemother, 9, 64, 10.1080/1120009X.1997.12113191 Wood, 1996, The comparative efficacy and safety of teicoplanin and vancomycin, J Antimicrob Chemother, 37, 209, 10.1093/jac/37.2.209 Hayakawa, 2001, An important notice of MRSA infection remedy based on therapeutic drug monitoring of teicoplanin, Jpn J Ther Drug Monit, 18, 328 Presterl, 1993, The efficacy of teicoplanin in the treatment of endocarditis caused by Gram-positive bacteria, J Antimicrob Chemother, 31, 755, 10.1093/jac/31.5.755